Remote Patient Monitoring: $175B Market and the AI That Powers It

Remote patient monitoring (RPM) — the use of digital tools to collect patient health data outside traditional clinical settings and transmit it to healthcare providers — crossed a regulatory threshold in 2019 that transformed it from a niche telehealth offering into a mainstream clinical service. That threshold was Centers for Medicare & Medicaid Services (CMS) billing code authorization for RPM services, establishing reimbursement pathways that made the business model viable at scale.

The CMS Billing Framework

CMS CPT codes 99453, 99454, 99457, and 99458 allow providers to bill for device setup, monthly data collection, and clinical staff review time associated with RPM programs. The 2023 and 2024 CMS Physician Fee Schedule updates expanded these codes and increased reimbursement rates, reflecting CMS’s assessment that RPM reduces hospital readmissions and emergency department utilization for high-risk patient populations.

As of 2025, over 2.5 million Medicare beneficiaries are enrolled in RPM programs — up from approximately 150,000 in 2020. The acceleration reflects both reimbursement availability and COVID-19’s lasting shift in patient and clinician willingness to engage with remote care modalities.

Market Size and Growth

Grand View Research projected the global RPM market at $175 billion by 2027, with a compound annual growth rate of 17.8%. North America accounts for approximately 40% of global market revenue, driven by the CMS reimbursement framework and the high penetration of connected devices among U.S. patients.

“RPM is not a niche product anymore — it is infrastructure. The question for health systems is not whether to deploy it, but how to do it without creating new operational burden.” — Digital Health Executive, 2025 HIMSS conference

The AI Layer: From Data Collection to Clinical Action

Raw RPM data — blood pressure readings, weight measurements, blood glucose levels, pulse oximetry — has limited clinical value without analytical infrastructure to contextualize and prioritize it. A patient enrolled in an RPM program for heart failure management may generate 30–50 data points per day. Without AI triage, the clinical staff reviewing this data faces an unmanageable volume.

The AI layer in RPM platforms performs several functions: anomaly detection (identifying readings outside patient-specific normal ranges), trend analysis (detecting gradual deterioration that individual readings may not capture), and priority scoring (ranking patients by risk to focus clinical review time). Companies including Validic, Propeller Health, Biofourmis, and Masimo’s RPM platform have built varying implementations of this infrastructure.

Clinical Evidence for RPM in Heart Failure

Heart failure is the highest-evidence RPM indication. Multiple randomized trials have demonstrated that daily weight monitoring with AI-driven alert thresholds reduces 30-day hospital readmissions — the quality metric that CMS ties to hospital reimbursement penalties. The BEAT-HF trial (2015) and subsequent real-world implementation studies have established an average 20–25% reduction in readmissions for patients enrolled in structured RPM programs.

Hypertension is the highest-volume RPM indication by enrolled patient count. The USPSTF and AHA/ACC hypertension guidelines now explicitly recommend home blood pressure monitoring as part of standard hypertension management, and CMS reimbursement has made RPM the natural vehicle for this monitoring in Medicare populations.

Operational Challenges

RPM programs face significant operational challenges that AI alone cannot solve. Device literacy and engagement among elderly Medicare beneficiaries — the population with the highest clinical need — is inconsistent. Studies show 30–40% dropout rates from RPM programs within the first 90 days, driven by device setup complexity, connectivity issues, and declining motivation after initial novelty wears off.

The health systems succeeding with RPM at scale have invested in dedicated patient engagement teams, simplified device onboarding, and proactive outreach protocols. The technology is a necessary but not sufficient condition for a functional RPM program.

Sources: CMS Physician Fee Schedule 2023–2024. Grand View Research, Remote Patient Monitoring Market Report, 2025. BEAT-HF trial results. AHA/ACC Hypertension Guidelines, 2024.